Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	CVnCoV 12 μg Vaccine	19,787
Overall Study	STARTED	Placebo	19,753
Overall Study	Phase 2b Participants	CVnCoV 12 μg Vaccine	2,007
Overall Study	Phase 2b Participants	Placebo	1,987
Overall Study	Phase 3 Participants	CVnCoV 12 μg Vaccine	17,780
Overall Study	Phase 3 Participants	Placebo	17,766
Overall Study	Rolled Over to Open-Label Phase	CVnCoV 12 μg Vaccine	8,513
Overall Study	Rolled Over to Open-Label Phase	Placebo	0
Overall Study	COMPLETED	CVnCoV 12 μg Vaccine	11,451
Overall Study	COMPLETED	Placebo	4,161
Overall Study	NOT COMPLETED	CVnCoV 12 μg Vaccine	8,336
Overall Study	NOT COMPLETED	Placebo	15,592

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04652102/flow